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Abstract
Background: XPA-binding protein 2 (XAB2) interacts with Cockayne syndrome complementation group A (CSA),
group B (CSB) and RNA polymerase II to initiate nucleotide excision repair. This study aims to evaluate the
association of XAB2 genetic variants with the risk of non-small cell lung cancer (NSCLC) using a tagging approach.
Methods: A hospital-based case-control study was conducted in 470 patients with NSCLC and 470 controls in
Chinese population. Totally, 5 tag single nucleotide polymorphisms (SNPs) in XAB2 gene were selected by
Haploview software using Hapmap database. Genotyping was performed using iPlex Gold Genotyping Asssy and
Sequenom MassArray. Unconditional logistic regression was conducted to estimate odd ratios (ORs) and 95 %
confidence intervals (95 % CI).
Results: Unconditional logistic regression analysis showed that the XAB2 genotype with rs794078 AA or at least
one rs4134816 C allele were associated with the decreased risk of NSCLC with OR (95 % CI) of 0.12 (0.03–0.54) and
0.46 (0.26–0.84). When stratified by gender, we found that the subjects carrying rs4134816 CC or CT genotype had a
decreased risk for developing NSCLC among males with OR (95 % CI) of 0.39 (0.18–0.82), but not among females. In
age stratification analysis, we found that younger subjects (age ≤ 60) with at least one C allele had a decreased risk
of NSCLC with OR (95 % CI) of 0.35 (0.17–0.74), but older subjects didn’t. We didn’t find that XAB2 4134816 C > T
variant effect on the risk of NSCLC when stratified by smoking status. The environmental factors, such as age, sex
and smoking had no effect on the risk of NSCLC related to XAB2 genotypes at other polymorphic sites.
Conclusions: The XAB2 tagSNPs (rs794078 and rs4134816) were significantly associated with the risk of NSCLC in
Chinese population, which supports the XAB2 plays a significant role in the development of NSCLC.
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Background
Worldwide, lung cancer harbored the highest incidence
and mortality rates among all malignant cancers [1, 2].
Non-small cell lung cancer (NSCLC), as the most com-
mon type of lung cancer, accounts for 75–80 % of all
lung cancer cases [3]. The development of lung cancer
was greatly affected by the environmental factors, such
as cigarette smoking, alcohol drinking and air pollutants
[4–6]. However, evidence has showed that the genetic
variants of cancer-related genes are associated with lung
risk, which the important role of genetic factors in the
development of lung cancer [7–9].
Nucleotide excision repair (NER) is the major DNA re-
pair pathway to remove bulky DNA lesions induced by
UV light and environmental carcinogens [10]. NER has
two subpathways, global genome NER (GG-NER) and
transcription coupling NER (TC-NER). TC-NER is in-
volved in a rapid removal of the damages on the tran-
scribed strands of active genes and a resumption of
transcription [11–13]. TC-NER is initiated by arresting
RNA polymerase II at DNA lesion site on transcript
strand. In the initiation of transcription coupling repair,
the TC-NER specific proteins Cockayne syndrome com-
plementation group A (CSA) and group B (CSB) are
thought to play an important role in removing the
stalled RNA polymorase II and recruiting other DNA
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repair proteins [14]. Many studies have demonstrated
that the decreased expression of CSA and CSB in lung
cancer and the genetic variants in these two genes were
associated with the lung cancer risk [15–18].
Xeroderma pigmentosum group A (XPA)-binding pro-
tein 2 (XAB2), which located at 19p13.2, was first identi-
fied as an interacting protein with XPA and hence found
to interact with CSA, CSB and RNA polymerase II to
participant to TC-NER and transcription [17, 19, 20]. In
vitro, when cells treated with DNA-damaging agents, en-
hanced interaction of XAB2 with RNA polymerase II or
XPA was observed, which suggesting DNA damage-
responsive activity of the XAB2 [19].
Due to the important role of XAB2 in the TC-NER, we
proposed that the genetic variants in XAB2 genes might
contribute to the risk of lung cancer. To verify this pro-
posal, we conducted this case-control study to evaluate




The study population has been described previously
[21]. Briefly, this hospital-based case-control study con-
sisted of 470 patients with NSCLC and 470 cancer-free
controls. All subjects were unrelated Han Chinese. All
patients with newly diagnosed, and previously untreated
primary lung cancer were recruited between January
2008 and December 2012 at Tangshan Gongren Hospital
(Tangshan, China). The exclusive criteria included previ-
ous cancer and previous radiotherapy or chemotherapy.
The controls were randomly selected from cancer-free
individuals living in the same region during the same
period as the cases were collected. The selection criteria
included no prior history of cancer. Controls were fre-
quency matched to the cases by age (±5 years) and sex.
At recruitment, informed consent was obtained from each
subject who was then interviewed for detailed information
on demographic characteristics and lifetime history of to-
bacco use. The study was approved by Ethics Committee
of Hebei United University (Approval No. 12–002).
Tag SNPs selection and genotyping
Based on the Han Chinese in Beijing (CHB) population
data from HapMap database, we used Haploview 4.2
program to select candidate tag SNPs with an r2 thresh-
old of 0.80 and minor allele frequency (MAF) greater
than 1 %. For XAB2 gene, we extended the 5′- and 3′-
untranslated regions (UTR) to include the 5′-UTR and
3′-UTR most SNP. As a result, 5 tagSNPs (2 in 5′ UTR,
2 in intron, 1 in exon region) in XAB2 were included,
which represent the common genetic variants in Chinese
population. Genotyping was performed at Bomiao Tech
(Beijing, China) using iPlex Gold Genotyping Asssy and
Sequenom MassArray (Sequenom, San Diego, CA,
USA). Sequenom’s MassArray Designer was used to de-
sign PCR and extension primers for each SNP. The in-
formation on assay conditions and the primers are
available upon request. Genotyping quality control con-
sisted of no-temple control samples for allele peaks and
verifying consistencies in genotype calls of 2 % randomly
selected duplicate sample. In addition, we excluded indi-
viduals and SNPs based on genotyping quality (<90 %
call rate).
Statistical analysis
The χ2 test was used to examine differences in demo-
graphic variables and the distribution of genotype be-
tween patients and controls. Hardy-Weinberg
equilibrium (HWE) for each SNP in controls was exam-
ined using Pearson goodness-of-fit χ2 test. The associ-
ation of each tag SNP with the risk of NSCLC was
estimated by odds ratios (ORs) and 95 % confidential in-
tervals (95 % CI) using unconditional logistic regression
adjusted by sex, age, and smoking status. Smokers were
considered current smokers if they smoked up to 1 year
before the date of cancer diagnosis for NSCLC patients
or before the date of the interview for controls. The
number of pack-years smoked was determined as an indi-
cation of cumulative cigarette-dose level [pack-year = (cig-
arettes per day/20) × (years smoked)]. Light and heavy
smokers were categorized by using the 50th percentile
pack-year value of the controls as the cut points (i.e., ≤25
and >25 pack-years). Statistical analysis was performed
using the SPSS version16.0 (SPSS Inc, Chicago, IL). A P
value of < 0.05 was considered as statistically significant.




The demographic characteristics of all participants are
presented in Table 1. The distribution of gender and
age among NSCLC cancer cases and healthy controls
were not significantly different (P = 0.832 for gender,
and P = 0.470 for age). There were also no significant
differences in the distribution of smoking status be-
tween cases and controls. However, the heavy
smokers (≥25 pack-year) accounted for 63.4 % in
cases and only 49.2 % in controls, which suggested
that cigarette smoking was a prominent contributor
to the risk of lung cancer. Among ever-smokers,
46,8 % (96) and 41.8 % (79) are former smokers in
lung cancer cases and controls, respectively. Of 470
NSCLC patients, 37.9 % (178) were adenocarcinoma,
50.6 % (238) was squamous cell carcinoma, and
11.5 % (54) were other types, including large cell car-
cinoma (n = 49) and mixed cell carcinoma (n = 5).
Pei et al. BMC Cancer  (2015) 15:560 Page 2 of 7
Selected SNPs and risk of developing NSCLC
The position and minor allele frequency (MAF) of the 5
selected tag SNPs in XAB2 gene were presented in
Table 2. For all selected SNPs, the distributions of geno-
type frequencies in controls were close to those expected
under Hardy Weinberg Equilibrium (HWE) (P > 0.05 for
all).
The observed genotype frequencies in participants and
the association of genotypes with the NSCLC were pre-
sented in Table 3. Of all selected SNPs in XAB2 genes,
two SNPs were identified to be associated with the risk
of NSCLC. For XAB2 rs794078 G > A polymorphism, we
found that AA genotype carriers had a significantly de-
creased risk for developing NSCLC (OR = 0.12; 95 %
CI = 0.03–0.54) in comparison to those with GG geno-
type. For XAB2 rs4134816 T > C polymorphism, just
one CC genotype was found among all individuals, so
we combined CT with CC genotype together for fur-
ther analysis. Our data showed that the subjects with
rs4134816 CT or CC genotype had a decreased risk of
NSCLC compared with those carrying TT genotype
with OR (95 % CI) of 0.46 (0.26–0.84). We didn’t find
that any other selected SNPs were associated with the
risk of NSCLC.
Stratification analysis of the XAB2 polymorphisms and the
risk of NSCLC
We then performed stratification analysis to evaluate the
effect of environmental factors on the association of
XAB2 polymorphisms with the risk of NSCLC (Table 4).
In dominant model, we found that the subjects carrying
rs4134816 CC or CT genotype had a decreased risk for
developing NSCLC among males with OR (95 % CI) of
0.39 (0.18–0.82), but not among females. When stratified
Table 1 Distributions of select characteristics in cases and
control subjects
Variables Cases (n = 470) Controls (n = 470) P valuea
No (%) No (%)
Gender 0.832
Male 324 68.9 328 69.8
Female 146 31.1 142 30.2
Age 0.470
<50 84 17.9 96 20.4
50–59 177 37.7 187 39.8
60–69 129 27.4 111 23.6
≥70 80 17.0 76 16.2
Smoking status 0.321
Non-smoker 265 56.4 281 59.8
Ever-smoker 205 43.6 189 40.2
Pack-year smoked 0.001
<25 75 36.6 96 50.8
≥25 130 63.4 93 49.2
atwo-side χ2 test
Table 2 Primary information of tag SNPs inXAB2gene
Gene and locus Rs number Contig position Location Base change MAF in controls P for HWE test Call rate (%)
XAB219p13.2 rs4134816 297747 5′ near gene T/C 0.04 0.998 100
rs4134819 297227 5′ near gene A/G 0.50 0.708 99.8
rs794083 295863 Intron C/G 0.33 0.157 100
rs4134860 290403 Intron T/C 0.15 0.978 100
rs794078 289839 T620T G/A 0.12 0.136 97.8
Table 3 Genotype frequencies of XAB2 and their association







OR (95 % CI)a P valuea
No (%) No (%)
rs4134816
TT 429 91.3 450 95.7
CT 40 8.5 20 4.3 0.49 (0.28–0.86) 0.012
CC 1 0.2 0 0.0 NC
CT + CC 41 8.7 20 4.3 0.46 (0.26–0.84) 0.010
rs4134819
AA 122 26.0 126 26.8
AG 226 48.0 237 50.4 0.96 (0.70–1.31) 0.797
GG 122 26.0 107 22.8 0.81 (0.56–1.16) 0.251
rs794083
CC 221 47.0 249 53.0
CG 189 40.2 161 34.2 0.72 (0.54–0.96) 0.023
GG 60 12.8 60 12.8 0.87 (0.58–1.31) 0.517
rs4134860
TT 341 72.6 332 70.7
CT 118 25.1 120 25.5 1.01 (0.75–1.36) 0.962
CC 11 2.3 18 3.8 1.73 (0.80–3.75) 0.163
rs794078
GG 365 77.7 374 79.6
AG 93 19.8 94 20.0 0.97 (0.70–1.35) 0.871
AA 12 2.5 2 0.4 0.12 (0.03–0.54) 0.006
AG + AA 105 22.3 96 20.4 0.87 (0.64–1.20) 0.396
aData were calculated by logistic regression and adjusted for sex, age
(categories), and smoking status
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Table 4 Association of XAB2 tagSNPs with NSCLC risk stratified by selected variables
Genetic Variant Variable Genotypes (Cases/Controls) Dominant model (AB + BB)/AAbOR (95 % CI)a P value
AAb AB + BBb
rs4134816 Sex
T > C Male 314/301 10/27 0.39 (0.18–0.82) 0.013
Female 136/128 10/14 0.68 (0.29–1.59) 0.370
Age
≤60 251/254 10/29 0.35 (0.17–0.74) 0.006
>60 199/175 10/12 0.98 (0.40–2.39) 0.970
Smoking status
Non-smoker 252/256 13/24 0.51 (0.26–1.03) 0.060
Ever-smoker 198/173 7/16 0.47 (0.19–1.20) 0.113
rs4134819 Sex
A > G Male 80/90 244/238 1.10 (0.77–1.58) 0.591
Female 46/32 100/110 0.64 (0.38–1.09) 0.098
Age
≤60 76/77 185/206 0.91 (0.63–1.33) 0.638
>60 50/45 159/142 0.92 (0.57–1.48) 0.726
Smoking status
Non-smoker 82/75 183/206 0.81 (0.56–1.17) 0.252
Ever-smoker 44/47 161/142 1.13 (0.70–1.82) 0.628
rs794083 Sex
C > G Male 169/159 155/169 0.88 (0.64–1.20) 0.415
Female 80/62 66/80 0.66 (0.41–1.05) 0.081
Age
≤60 139/140 122/143 0.90 (0.64–1.27) 0.546
>60 110/81 99/106 0.71 (0.47–1.07) 0.098
Smoking status
Non-smoker 144/139 121/142 0.81 (0.58–1.14) 0.226
Ever-smoker 105/82 100/107 0.74 (0.49–1.11) 0.141
rs4134860 Sex
T > C Male 227/237 97/91 1.14 (0.80–1.61) 0.470
Female 105/104 41/38 1.11 (0.66–1.87) 0.702
Age
≤60 186/211 75/72 1.24 (0.84–1.82) 0.275
>60 146/130 63/57 0.97 (0.63–1.51) 0.906
Smoking status
Non-smoker 190/207 75/74 1.10 (0.76–1.61) 0.608
Ever-smoker 142/134 63/55 1.05 (0.67–1.63) 0.841
rs794078 Sex
G > A Male 256/256 68/72 0.92 (0.63–1.35) 0.673
Female 118/109 28/33 0.79 (0.45–1.40) 0.426
Age
≤60 208/226 53/57 1.04 (0.68–1.58) 0.872
>60 166/139 43/48 0.74 (0.46–1.20) 0.226
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by gender, we observed a positively significant inter-
action between rs4134816 genotypes and gender on de-
creasing NSCLC risk (P = 0.034). Our data also showed
that younger subjects (age ≤ 60) with at least one C allele
had a decreased risk of NSCLC with OR (95 % CI) of
0.35 (0.17–0.74), but older subjects didn’t. However,
there was no gene-environment interaction observed
(P = 0.094). We didn’t find that XAB2 4134816 C > T
variant effect on the risk of NSCLC when stratified by
smoking status. The environmental factors, such as age,
sex and smoking had no effect on the risk of NSCLC
related to XAB2 genotypes at other polymorphic sites
(Table 4).
Discussion
In this case-control study in a Chinese population, we
found that two tag SNPs (rs794078 and rs4134816) in
XAB2 were associated with significantly decreased risk
of development non-small cell lung cancer. These find-
ings indicated that XAB2 genetic variants might contrib-
ute to the susceptibility of lung cancer.
Nucleotide excision repair is the main mechanism for
removing the bulky DNA adduct from damage DNA for
preventing carcinogens-induced mutagenesis [22, 23].
Several animal models, where individual NER genes
were disrupted, had showed the importance of the integ-
rity of NER pathway in preventing lung cancer [24, 25].
TC-NER, as one of important sub-pathways in NER,
only repairs the lesions in the transcribed strand in ac-
tive genes. There are several major proteins involved in
TC-NER in human cells, including CSA, CSB, XPA and
XAB2. Studies have showed that the deficient of these
nucleotide excision repair proteins contributed to the
risk of various cancers. Animal experiments showed that
the CSB played an important role in the cellular response
to stress and CSB−/− mice were increased susceptible to
chemically induced skin cancer [26]. A case-control study
also found 12.2 and 12.5 % reduced RNA transcriptional
levels of CSA and CSB in lung cancer patients than
controls [27].
XAB2 is a key factor in TC-NER, which is composed
of 855 amino acids and contains 15 tetratricopeptide re-
peat motifs. By interacting with CSA, CSB, RNA poly-
merase II and XPA, XAB2 conducted the multiple
functions in the process of transcription and TC-NER
[19, 20]. Microinjection of specific antibodies against
XAB2 inhibits transcription and TC-NER, suggesting the
key role of XAB2 in the process of transcription and
TC-NER [20]. Knockdown of XAB2 in HeLa cell re-
sulted in a hypersensitivity to killing by UV light and a
decreased recovery of RNA synthesis [19]. Over expres-
sion of XAB2 was observed in HL60 cells treated with
inhibited all-trans retinoic acid (ATRA) and inhibited
XAB2 expression by small interfering RNA (siRNA) in-
creased ATRA-sensitive cellular differentiation, which
indicated that XAB2 was associated with the cellular dif-
ferentiation [28].
Studies have demonstrated that the polymorphisms,
which located in NER genes or regulatory sequences,
may affect DNA repair capacity and further increase
likelihood of cancer development. In the present study
of NSCLC in Chinese, we used a relatively comprehen-
sive selection of SNPs and found the significant effects
of XAB2 variants on the risk of lung cancer. This is the
first study to investigate the association of XAB2 poly-
morphisms with the risk for developing cancer. There
were several studies to evaluate the role of XAB2 genetic
variants in complex autoimmune disease. For example,
Briggs et al. conducted a case-control study to evaluate
the correlation between XAB2 rs4134860 T > C variant
and the risk of multiple sclerosis (MS) and found an in-
creased risk of MS among rs4134860 CC genotype car-
riers [29]. In this lung cancer case-control study, we
didn’t find any association of XAB2 rs4134860 T > C
polymorphism with the risk of NSCLC. In another study,
researchers analyzed the impact of several polymorphisms
in DNA repair genes on the prognosis of colorectal cancer
patients and didn’t find the association of XAB2 rs794078
G >A variant with the cancer prognosis [30]. In present
study, individuals carrying XAB2 rs794078 AA genotype
had 88 % decreased risk of NSCLC.
As we know, the magnitude of the effect of smoking
far outweighed all other factors leading to lung cancer
[31, 32]. Many studies have demonstrated that the strong
association of smoking with lung cancer risk [5, 33, 34].
Therefore, we further analyzed the role of XAB2 polymor-
phisms in the development of NSCLC stratified by smok-
ing status. We observed that a 49 % protective effect for
XAB2 rs4134816 variant was evident only for non-
smokers, but not for smokers. The exact mechanism of
Table 4 Association of XAB2 tagSNPs with NSCLC risk stratified by selected variables (Continued)
Smoking status
Non-smoker 211/225 54/56 1.02 (0.67–1.55) 0.930
Ever-smoker 163/140 42/49 0.73 (0.45–1.18) 0.202
aData were calculated by unconditional logistic regression and adjusted for gender, age (categories), and smoking status, where it was appropriate
bA stands for Major allele and B stands for Minor allele for each SNP
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how cigarette-smoking effects on DNA repair capacity
posted by XAB2 polymorphism is unknown. One possible
explanation may be that the protective effect of XAB2
variant allele might be evident in non-smokers with low
levels of oxidative damage. Similar pattern of genetic ef-
fects have been observed for DNA repair gene
XRCC1 (X-ray repair cross-complementation group 1)
at low smoking exposure, but not at high smoking
exposure [35].
When stratified by gender, our study showed a 61 %
protective effect of XAB2 rs4134816 C genotype among
men, but not among women. Genetic variants in NER
genes are associated with variability of lung cancer risk.
Letkova and his colleagues investigated the polymor-
phisms of selected DNA repair genes, including XPC,
XPD, hOGG1 and XRCC1, and found the different risks
of developing lung cancer when stratified by gender,
which further supporting our current findings [36]. Our
present study also found that a 65 % protective effect for
XAB2 rs4134816 T > C genetic variant among subjects
aged 60 years or younger. Using Cox proportional haz-
ard model, Gauderman et al. estimated the age-specific
genetic incidence rate and found that the estimated pro-
portion of lung cancer patients with high-risk allele ex-
ceeds 90 % for cases with onset at age 60 years or less
and decreases to approximately 10 % for cases with on-
set at age 80 years or older. These findings suggested the
contribution of age in the development of cancer [37].
The numbers of subjects in several of subgroups were
very small, so some caution is needed when interpreting
these findings.
Our study has its limitation. Due to the moderate sam-
ple size and the lack of related phenotypic and func-
tional assays, large studies and functional evaluations are
still need to be conducted in the future.
Conclusions
In conclusion, we have genotyped 5 tag SNPs in XAB2
gene in this NSCLC case-control set. We found the evi-
dence of significant association with the risk of NSCLC
for two tag SNPs (rs794078 and rs4134816) in XAB2
gene in Chinese population. These results further sup-
ported that XAB2 play a significant role in the develop-
ment of NSCLC.
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